Active Not RecruitingNCT05543681
IGC-AD1 for agitation in Alzheimer’s disease
About this title
Read the official source — NCT05543681Medication studyAges 60+United States + CanadaAnxiety
Understand this study
Who could participate?
Listed age limits: from 60 years.
- Listed locations
- Maitland and 27 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 11, 2022
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 164
- Sponsor
- IGC Pharma, LLC
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- Over 60 Years
- Official registry ID
- NCT05543681
- Official title
Show the full official title
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Maitland, United States · Melbourne, United States · Miami, United States
21 more locations
- Port Charlotte, United States
- Tampa, United States
- Metairie, United States
- Baltimore, United States
- Clinton, United States
- Olney, United States
- St Louis, United States
- Amherst, United States
- Brooklyn, United States
- Syracuse, United States
- Oklahoma City, United States
- Providence, United States
- Austin, United States
- Dallas, United States
- Richmond, United States
- Victoria, Canada
- Hamilton, Canada
- Toronto, Canada
- Montreal, Canada
- Bayamón, Puerto Rico
- Rio Piedras, Puerto Rico
Questions about this study
Who is behind this study?
The study sponsor is IGC Pharma, LLC, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including IGC-AD1-Active and IGC-AD1-Placebo.
Who can participate?
Listed age limits: from 60 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
